menu
    • menu

    Find Pegfilgrastim manufacturers, exporters & distributors on PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    1

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    1

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 11,435,344

    MARKET PLACE

    3

    API

    7

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    39

    FDF Dossiers

    FDF Dossiers

    7

    FDA Orange Book

    FDA (Orange Book)

    12

    Europe

    Europe

    6

    Canada

    Canada

    6

    Australia

    Australia

    6

    South Africa

    South Africa

    2

    Listed Dossiers

    Listed Dossiers

    38DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    1

    USP

    0

    JP

    1

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    9

    Health Canada Patents

    DIGITAL CONTENT

    13

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    229

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    96,791,099

    Annual Reports

    28,412

    Finished Drug Prices

    Listed Dossiers

    22 RELATED EXCIPIENT COMPANIES

    40EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as:
    Molecular Formula
    C27H46N4O19
    Molecular Weight
    730.7  g/mol
    InChI Key
    GAQMWPRWVIGRRV-IVDGIBIRSA-N
    Pegfilgrastim
    1 2D Structure

    Pegfilgrastim

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2R,4S,5R,6R)-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(1S,2R)-1-amino-1-carboxypropan-2-yl]oxy-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-5-[[2-(2-methoxyethoxycarbonylamino)acetyl]amino]-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
    2.1.2 InChI
    InChI=1S/C27H46N4O19/c1-10(16(28)23(40)41)48-24-18(30-11(2)33)21(39)20(38)14(49-24)9-47-27(25(42)43)6-12(34)17(22(50-27)19(37)13(35)8-32)31-15(36)7-29-26(44)46-5-4-45-3/h10,12-14,16-22,24,32,34-35,37-39H,4-9,28H2,1-3H3,(H,29,44)(H,30,33)(H,31,36)(H,40,41)(H,42,43)/t10-,12+,13-,14-,16+,17-,18-,19-,20+,21-,22-,24+,27-/m1/s1
    2.1.3 InChI Key
    GAQMWPRWVIGRRV-IVDGIBIRSA-N
    2.1.4 Canonical SMILES
    CC(C(C(=O)O)N)OC1C(C(C(C(O1)COC2(CC(C(C(O2)C(C(CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C
    2.1.5 Isomeric SMILES
    C[C@H]([C@@H](C(=O)O)N)O[C@@H]1[C@@H]([C@H]([C@H]([C@H](O1)CO[C@@]2(C[C@@H]([C@H]([C@@H](O2)[C@@H]([C@@H](CO)O)O)NC(=O)CNC(=O)OCCOC)O)C(=O)O)O)O)NC(=O)C
    2.2 Create Date
    2013-02-04
    3 Chemical and Physical Properties
    Molecular Weight 730.7 g/mol
    Molecular Formula C27H46N4O19
    XLogP3-8.6
    Hydrogen Bond Donor Count12
    Hydrogen Bond Acceptor Count20
    Rotatable Bond Count19
    Exact Mass730.27562525 g/mol
    Monoisotopic Mass730.27562525 g/mol
    Topological Polar Surface Area365 Ų
    Heavy Atom Count50
    Formal Charge0
    Complexity1170
    Isotope Atom Count0
    Defined Atom Stereocenter Count13
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1

    Listed Suppliers

    read-more
    read-more

    01

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    SupplySide West 2024
    Not Confirmed
    arrow

    Nanogen Pharmaceutical Biotechnolog...

    Vietnam
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Vietnam
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Pegfilgrastim

    About the Company : Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are pro...

    Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are proud to be the leading company in the Asia-Pacific region that successfully researched and developed Active Pharmaceutical Ingredients (APIs) and specific therapeutic products on the foundation of advanced recombinant DNA/protein technology.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1651429800,"product":"PEGFILGRASTIM (PEGILATED FILGRASTIM),CON","address":"CAMUS HOUSE, 29-B, SURAJ NAGAR EAST, CIVIL LINES,","city":"JAIPUR, RAJASTHAN.","supplier":"CAMUS PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"PSK PHARMA LTD.","customerCountry":"RUSSIA","quantity":"0.03","actualQuantity":"31.925","unit":"GMS","unitRateFc":"11020","totalValueFC":"343439.9","currency":"USD","unitRateINR":831417.3844949099,"date":"02-May-2022","totalValueINR":"26543000","totalValueInUsd":"343439.9","indian_port":"BOMBAY AIR","hs_no":"29379090","bill_no":"1128975","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CAMUS HOUSE, 29-B, SURAJ NAGAR EAST, CIVIL LINES,, JAIPUR, RAJASTHAN.","customerAddress":""}]
    02-May-2022
    02-May-2022
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lupin Gains Health Canada Approval for Biosimilar Pegfilgrastim

    Details:

    Armlupeg (pegfilgrastim) is a biosimilar of Neulasta, that acts as a G-CSF agonist & it is indicated for the treatment of patients suffering from febrile neutropenia.


    Lead Product(s): Pegfilgrastim

    Therapeutic Area: Hematology Brand Name: Armlupeg

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 23, 2024

    blank

    01

    Lupin Ltd

    India
    arrow
    World Vaccine Congress
    Not Confirmed

    Lupin Ltd

    India
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pegfilgrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lupin Gains Health Canada Approval for Biosimilar Pegfilgrastim

    Details : Armlupeg (pegfilgrastim) is a biosimilar of Neulasta, that acts as a G-CSF agonist & it is indicated for the treatment of patients suffering from febrile neutropenia.

    Brand Name : Armlupeg

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    August 23, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    VGXI, Sutro Partner to Support Sutro's Clinical Pipeline

    Details:

    The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.


    Lead Product(s): Luveltamab Tazevibulin,Pegfilgrastim

    Therapeutic Area: Oncology Brand Name: Luvelta

    Study Phase: Phase II/ Phase IIIProduct Type: Large molecule

    Sponsor: Sutro Biopharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership June 03, 2024

    blank

    02

    VGXI

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    VGXI

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

    Therapeutic Area : Oncology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Sutro Biopharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    VGXI, Sutro Partner to Support Sutro's Clinical Pipeline

    Details : The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.

    Brand Name : Luvelta

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    June 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

    Details:

    STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated for ovarian cancers in combination with Pegfilgrastim.


    Lead Product(s): Luveltamab Tazevibulin,Pegfilgrastim

    Therapeutic Area: Oncology Brand Name: Luvelta

    Study Phase: Phase II/ Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 30, 2024

    blank

    03

    Sutro Biopharma

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    Sutro Biopharma

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

    Therapeutic Area : Oncology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

    Details : STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated for ovarian cancers in combination with Pegfilgrastim.

    Brand Name : Luvelta

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    April 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sunshine Biopharma's Nora Pharma Receives Approval for Niopeg(R) Biosimilar

    Details:

    Niopeg (pegfilgrastim) is an FDA-approved G-CSF agonist for treating febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.


    Lead Product(s): Pegfilgrastim

    Therapeutic Area: Hematology Brand Name: Niopeg

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 19, 2024

    blank

    04

    Nora Pharma

    Canada
    arrow
    World Vaccine Congress
    Not Confirmed

    Nora Pharma

    Canada
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pegfilgrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Sunshine Biopharma's Nora Pharma Receives Approval for Niopeg(R) Biosimilar

    Details : Niopeg (pegfilgrastim) is an FDA-approved G-CSF agonist for treating febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.

    Brand Name : Niopeg

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    April 19, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

    Details:

    Sutro intends to use the net proceeds of this offering to fund research, clinical, and development of STRO-002 (Luveltamab Tazevibulin) with Neulasta for FOLR1-expressed Ovarian Neoplasms.


    Lead Product(s): Luveltamab Tazevibulin,Pegfilgrastim

    Therapeutic Area: Oncology Brand Name: STRO-002

    Study Phase: Phase IIProduct Type: Large molecule

    Sponsor: BofA Securities

    Deal Size: $75.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering April 02, 2024

    blank

    05

    Sutro Biopharma

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    Sutro Biopharma

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : BofA Securities

    Deal Size : $75.0 million

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

    Details : Sutro intends to use the net proceeds of this offering to fund research, clinical, and development of STRO-002 (Luveltamab Tazevibulin) with Neulasta for FOLR1-expressed Ovarian Neoplasms.

    Brand Name : STRO-002

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    April 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Coherus Launches UDENYCA ONBODY™ Delivery System for Pegfilgrastim

    Details:

    Udenyca Onbody is an on-body injector of Udenyca® (pegfilgrastim-cbqv), indicated to reduce infection incidence in non-myeloid malignancy patients.


    Lead Product(s): Pegfilgrastim

    Therapeutic Area: Hematology Brand Name: Udenyca Onbody

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 21, 2024

    blank

    06

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pegfilgrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Coherus Launches UDENYCA ONBODY™ Delivery System for Pegfilgrastim

    Details : Udenyca Onbody is an on-body injector of Udenyca® (pegfilgrastim-cbqv), indicated to reduce infection incidence in non-myeloid malignancy patients.

    Brand Name : Udenyca Onbody

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    February 21, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Coherus Announces FDA Approval of UDENYCA ONBODY, a Novel and Proprietary State-of-the-Art Delivery System for Pegfilgrastim-cbqv

    Details:

    Udenyca (pegfilgrastim-cbqv), is a FDA-approved biosimilar that acts as a G-CSF agonist for the treatment of patients with non-myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia.


    Lead Product(s): Pegfilgrastim

    Therapeutic Area: Hematology Brand Name: Udenyca

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 26, 2023

    blank

    07

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pegfilgrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Coherus Announces FDA Approval of UDENYCA ONBODY, a Novel and Proprietary State-of-the-Art Deliver...

    Details : Udenyca (pegfilgrastim-cbqv), is a FDA-approved biosimilar that acts as a G-CSF agonist for the treatment of patients with non-myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febri...

    Brand Name : Udenyca

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    December 26, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™

    Details:

    Udenyca Onbody (pegfilgrastim-cbqv) Autoinjector products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.


    Lead Product(s): Pegfilgrastim

    Therapeutic Area: Hematology Brand Name: Udenyca Onbody

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 05, 2023

    blank

    08

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pegfilgrastim

    Therapeutic Area : Hematology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONB...

    Details : Udenyca Onbody (pegfilgrastim-cbqv) Autoinjector products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona...

    Brand Name : Udenyca Onbody

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    October 05, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY„¢ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings...

    Details:

    Udenyca Onbody (pegfilgrastim-cbqv) Autoinjector products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.


    Lead Product(s): Pegfilgrastim

    Therapeutic Area: Hematology Brand Name: Udenyca Onbody

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 25, 2023

    blank

    09

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    Coherus Biosciences

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pegfilgrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY„¢ Biologics License Application ...

    Details : Udenyca Onbody (pegfilgrastim-cbqv) Autoinjector products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona...

    Brand Name : Udenyca Onbody

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    September 25, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Monopar Provides Encouraging Camsirubicin Clinical Data Update

    Details:

    MNPR-201 (camsirubicin) is a novel proprietary analog of widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas.


    Lead Product(s): Camsirubicin,Pegfilgrastim

    Therapeutic Area: Oncology Brand Name: MNPR-201

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 08, 2023

    blank

    10

    Monopar Therapeutics

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed

    Monopar Therapeutics

    U.S.A
    arrow
    World Vaccine Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Camsirubicin,Pegfilgrastim

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Monopar Provides Encouraging Camsirubicin Clinical Data Update

    Details : MNPR-201 (camsirubicin) is a novel proprietary analog of widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leuk...

    Brand Name : MNPR-201

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    August 08, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Film Formers & Plasticizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search